US seniors' Rx cost rises "are double inflation"

14 June 2001

Prices of the 50 prescription drugs most commonly used by olderAmericans rose 6.1% on average in the 12 months ending January 2001, compared with an overall inflation rate for the period of 3.4%, according to a new report published by Families USA.

Using data from the Pennsylvania Pharmaceutical Assistance Contract for the Elderly, which is described as USA's largest outpatient prescription drug program, the study says the prices of 38 of the drugs had risen by at least 150% the rate of inflation, and more than one third went up by three or more times the inflation rate.

Seniors' average annual cost per prescription in the period was $956. The most expensive drugs most commonly used by seniors included Pharmacia's COX-2 inhibitor Celebrex (celecoxib), at $1,837; Merck & Co's statin Zocor (simvastatin), at $1,520 and AstraZeneca's antiulcerant Prilosec (omeprazole), costing $1,511.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight